S S Engel

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cardiovasc Diabetol 12:3. 2013
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
  3. pmc Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
    S S Engel
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pract 64:984-90. 2010
  4. ncbi request reprint Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk
    K G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Diabetes Obes Metab 14:1123-8. 2012
  5. doi request reprint Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database
    K G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ 19454, USA
    Int J Clin Pract 67:449-54. 2013

Collaborators

Detail Information

Publications5

  1. pmc Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cardiovasc Diabetol 12:3. 2013
    ..To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators...
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
    ..The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies...
  3. pmc Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
    S S Engel
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pract 64:984-90. 2010
    ..0.10 events per 100 patient-years, respectively). Preclinical and clinical trial data with sitagliptin to date do not indicate an increased risk of pancreatitis in patients with T2DM treated with sitagliptin...
  4. ncbi request reprint Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk
    K G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Diabetes Obes Metab 14:1123-8. 2012
    ..To examine the impact of diabetes duration, chronic pancreatitis and other factors on pancreatic cancer risk...
  5. doi request reprint Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database
    K G Brodovicz
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ 19454, USA
    Int J Clin Pract 67:449-54. 2013
    ..other oral antihyperglycaemic agents (OAHA) during the initial 2 years following sitagliptin's introduction in the U.S. continued during the second 2 years of sitagliptin availability...